Alembic Pharmaceuticals reports Q1 FY27 results with 26% rise in revenue and strong segment performance
Alembic Pharmaceuticals Limited has reported its consolidated financial outcomes for the first quarter of the fiscal year 2027, ending June 30, 2026. The company posted a 26% year-on-year increase in revenue from operations, while Profit After Tax stood at Rs. 173 Cr, marking a 12% growth. EBITDA pre R&D reached Rs. 523 Cr, corresponding to a 24% margin.Commenting on the results, Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, stated that the company began FY27 strongly, driven by broad-based growth across its businesses. He attributed the performance to healthy volume growth, successful new product launches, and effective execution in key markets. The US business delivered significant momentum, while other markets recorded steady growth. Alembic remains focused on advancing its pipeline, strengthening its product portfolio, and ensuring sustainable long-term growth.
International and Domestic Business Segments Perform Well
The international business segment showed particularly strong growth. US Formulation revenues grew by 49% to Rs. 778 Cr, and the company executed seven launches in the US market during the quarter. Ex-US Generics saw a 17% increase, generating Rs. 383 Cr. Furthermore, the International division secured 10 ANDA approvals during the period.In the domestic segment, the India Branded Business achieved a 7% year-on-year growth, with revenue reaching Rs 642 Cr for the quarter. Robust growth was noted in Gynaecology, Gastrology, and Ophthalmology. The Animal healthcare segment also demonstrated encouraging performance. During the quarter, 3 new products were introduced within the Indian market.
The API business component experienced a substantial rise of 33%, generating Rs. 346 Cr in revenue.
Consolidated Revenue Breakdown
Consolidated revenues across all segments contributed to the overall increase in revenue from operations, which grew by 26%. The segment-wise breakdown for Q1 FY27 is detailed below:| Particulars | Q1 FY26 (Rs Cr) | Q1 FY27 (Rs Cr) | % Change |
|---|---|---|---|
| India | 599 | 642 | 7% |
| USA | 523 | 778 | 49% |
| Ex-US | 328 | 383 | 17% |
| API | 261 | 346 | 33% |
| Total | 1711 | 2150 | 26% |
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products globally, possessing state-of-the-art research and manufacturing facilities approved by regulatory authorities of several developed countries, including the US FDA.
APLLTD Stock Price Movement
Shares of Alembic Pharmaceuticals Limited are edging higher to ₹806.3 as of 2:44 PM today, recording a marginal gain of 0.07%. The stock maintains strong intraday trading within its range, having seen touches between the low of ₹803.95 and the high of ₹825.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.